Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
G6PD, quantitative; red blood cell count (RBC)
2 - 4 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
8 mL (4 mL in each of two tubes)
RBC: Two 500-μL lavender-top Microtainer™ tubes filled to at least 50% of tube capacity. (Note: If any other size lavender tube is used, the tube must be filled to at least 50% capacity of tube fill volume. Insufficient volume may limit the extent of procedures performed.) and G6PD: One lavender-top (EDTA) tube, green-top (heparin) tube, or yellow-top (ACD) tube (0.1 mL) whole blood.
Two lavender-top (EDTA) tubes; or one green-top (heparin) tube and one lavender-top (EDTA) tube; or one yellow-top (ACD) tube and one lavender-top (EDTA) tube
RBC: Stable refrigerated for 72 hours. G6PD: stable refrigerated for seven days.
RBC: Hemolysis; tube not filled with minimum fill volume; specimen drawn in any anticoagulant other than EDTA; specimens diluted or contaminated with IV fluid; clotted specimen; improper labeling; transfer tubes with whole blood; lavender-top (EDTA) tubes received with plasma removed; samples more than 72 hours old. G6PD: Frozen specimen; clotted specimen.
Evaluate glucose 6-phosphate dehydrogenase (G6PD) deficiency.G6PD deficiency, an X-linked disorder, is the most common enzymatic disorder of red blood cells in humans, affecting more than 400 million people worldwide. The clinical expression of G6PD variants encompasses a spectrum of hemolytic syndromes. Affected patients are most often asymptomatic, but many patients have episodic anemia, while a few have chronic hemolysis.
With the most prevalent G6PD variants (G6PD A- and G6PD Mediterranean), hemolysis is induced in children and adults by the sudden destruction of older, more deficient erythrocytes after exposure to drugs having a high redox potential (including the antimalarial drug primaquine and certain sulfa drugs) or to fava beans, selected infections, or metabolic abnormalities. In the neonate with G6PD deficiency, however, decreased bilirubin elimination may play an important role in the development of jaundice.
G6PD deficiency should be suspected in any subject with an episode of nonimmune hemolytic anemia, especially if occurring after drug ingestion, infection, or an episode of diabetic ketoacidosis.
False normal results after hemolysis may occur; vide infra. See Additional Information.
Levels of G6PD are higher in the newborn than they are in the adult.
When high levels are seen in older patients, it invariably reflects the presence of a young red blood cell population with reticulocytosis.
Kinetic − 340 nm
Male (units/trillion RBCs)
Female (units/trillion RBCs)
0 to 30 d
31 d to 6 m
7 m to 12 y
13 to 17 y
18 to 30 y
G6PD hemolysis is associated with formation of Heinz bodies in peripheral red blood cells. It is the older erythrocytes that are most G6PD-deficient in affected individuals. These cells are first eliminated in a hemolytic crisis. The younger cells and reticulocytes contain more G6PD. For these reasons, after a hemolytic crisis, when only younger erythrocytes and reticulocytes are present, the G6PD values may be spuriously normal.
These "false-negative" (ie, spuriously normal or high) results are a potential concern because the most severely deficient red cells have already been removed from the circulation via hemolysis.
This problem is usually not important when testing male Caucasians but is a concern in some Caucasian females and blacks of both sexes, especially during the reticulocytosis following acute hemolysis. When a false-negative test is suspected, the best approach is to reëvaluate the patient three months after the hemolytic episode, a time at which the red cell mass will have been repopulated with red cells of all ages.
To prevent future hemolytic episodes, subjects with G6PD deficiency should avoid drugs and chemicals with oxidant potential. A partial list of safe and unsafe drugs is given in following table.
Unsafe for Class I, II, and III Variants
Safe for Class II and III Variants
*Note: This is a partial list only.
Source: Beutler E. G6PD deficiency. Blood. 1994 Dec 1; 84(11):3613-3636.
Ascorbic acid (except in very high doses)
Naphthalene (mothballs, henna)
Uricase (rasburicase, pegloticase)
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|001917||G6PD,Qn,Bld and Red Cell Count||005033||RBC||x10E6/uL||789-8|
|001917||G6PD,Qn,Bld and Red Cell Count||001927||G-6-PD, Quant||U/10E12 RBC||49502-8|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf